Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)
Recruiting · NCT07364331 · Interventional (participants receive a specific treatment) · Lead sponsor: China Medical University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Omega-3Placebo
What this trial is about
This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.
Who can take part
Age range
6 Years to 18 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- DSM-5 diagnosis of ADHD
- Did not have any changes of ADHD treatment (pharmacological/psychological) within 4 weeks of entering the trial.
- SNAP-IV inattention subscale \>=12, or hyperactivity subscale \>=12, or inattention+ hyperactivity subscales \>=24
Exclusion criteria
- IQ\<80
- Allergic to omega-3
- Physical disorders: thyroid function, cancer
- Psychiatric comorbidity: SUD, psychotic disorders, bipolar disorder, major depressive disorder
Where it is running
1 location listed.
- China Medical University Hospital - Taichung, Taiwan